Home
HOTH
HOTH News

Latest Hoth Therapeutics Inc. (HOTH) News on September 13, 2025

Hoth Therapeutics Taps Lantern Pharma's PredictBBB.ai Platform -- Breakthrough AI With 94% Accuracy Driving Next-Gen Drug Development

PR Newswire

9 days ago

Hoth Therapeutics Taps Lantern Pharma's PredictBBB.ai Platform -- Breakthrough AI With 94% Accuracy Driving Next-Gen Drug Development

Hoth Therapeutics' Cancer Therapeutic HT-KIT Surpasses Preclinical Milestones With Potent Anti-Tumor Activity and GLP-Validated Bioanalytical Results, Exceeding Regulatory Standards

PR Newswire

11 days ago

Hoth Therapeutics' Cancer Therapeutic HT-KIT Surpasses Preclinical Milestones With Potent Anti-Tumor Activity and GLP-Validated Bioanalytical Results, Exceeding Regulatory Standards

EXCLUSIVE: Hoth Therapeutics' Antisense Therapy Demonstrates Efficacy Against KIT-Driven Cancers

Benzinga

11 days ago

EXCLUSIVE: Hoth Therapeutics' Antisense Therapy Demonstrates Efficacy Against KIT-Driven Cancers

MT Newswires

3 months ago

Silo Pharma, Hoth Therapeutics to Launch Joint Venture for Obesity Treatment

Hoth Therapeutics says HT-001 met primary endpoint in CLEER-001 study

TipRanks

3 months ago

Hoth Therapeutics says HT-001 met primary endpoint in CLEER-001 study

Silo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market

GlobeNewswire

3 months ago

Silo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market

Hoth Therapeutics (HOTH) and Silo Pharma (NASDAQ: SILO) today announced the formation of a 50/50 joint venture to develop a first-in-class GDNF-based therapy licensed from the U.S. Department of Veterans Affairs. The therapy targets obesity and fatty liver disease.

PR Newswire

3 months ago

Hoth Therapeutics (HOTH) and Silo Pharma (NASDAQ: SILO) today announced the formation of a 50/50 joint venture to develop a first-in-class GDNF-based therapy licensed from the U.S. Department of Veterans Affairs. The therapy targets obesity and fatty liver disease.

MT Newswires

3 months ago

Sector Update: Health Care Stocks Higher in Afternoon Trading

Hoth Therapeutics HT-001 Interim Results First-in-Class Topical Therapy Preserves Cancer Treatment While Resolving Dermatologic Side Effects

PR Newswire

3 months ago

Hoth Therapeutics HT-001 Interim Results First-in-Class Topical Therapy Preserves Cancer Treatment While Resolving Dermatologic Side Effects

Hoth Therapeutics to host KOL Event Spotlighting HT-001, Novel Therapy

PR Newswire

3 months ago

Hoth Therapeutics to host KOL Event Spotlighting HT-001, Novel Therapy

MT Newswires

3 months ago

Hoth Therapeutics Regains Nasdaq Compliance

Hoth Therapeutics Regains Nasdaq Compliance - Clears Key Listing Hurdle, Reaffirms Path Toward Growth

PR Newswire

3 months ago

Hoth Therapeutics Regains Nasdaq Compliance - Clears Key Listing Hurdle, Reaffirms Path Toward Growth

Hoth Therapeutics Reports Positive Preclinical Safety Data for Cancer Fighting HT-KIT -- Dose-Dependent Liver Activity with No Observed Toxicity Supports IND Pathway

PR Newswire

3 months ago

Hoth Therapeutics Reports Positive Preclinical Safety Data for Cancer Fighting HT-KIT -- Dose-Dependent Liver Activity with No Observed Toxicity Supports IND Pathway

Hoth Therapeutics to Attend 2025 BIO International Convention

PR Newswire

3 months ago

Hoth Therapeutics to Attend 2025 BIO International Convention

Hoth Therapeutics Secures Japanese Patent for Breakthrough HT-KIT Platform Targeting Mast Cell Diseases

PR Newswire

3 months ago

Hoth Therapeutics Secures Japanese Patent for Breakthrough HT-KIT Platform Targeting Mast Cell Diseases

Hoth Therapeutics Launches Expanded Access Initiative for HT-001, Offering Critical Relief to Cancer Patients Facing Severe Skin Toxicities

PR Newswire

3 months ago

Hoth Therapeutics Launches Expanded Access Initiative for HT-001, Offering Critical Relief to Cancer Patients Facing Severe Skin Toxicities

Hoth Therapeutics to Spotlight HT-001 in Investor-Focused KOL Event Addressing Breakthrough Combating Cancer Treatment Skin Toxicities

PR Newswire

3 months ago

Hoth Therapeutics to Spotlight HT-001 in Investor-Focused KOL Event Addressing Breakthrough Combating Cancer Treatment Skin Toxicities

/C O R R E C T I O N -- Hoth Therapeutics, Inc./

PR Newswire

4 months ago

/C O R R E C T I O N -- Hoth Therapeutics, Inc./

Hoth Therapeutics Announces Granted Japanese Patent for Novel RNA-Based Cancer Therapy Targeting KIT Gene - Expands Global IP in Precision Oncology Platform

PR Newswire

5 months ago

Hoth Therapeutics Announces Granted Japanese Patent for Novel RNA-Based Cancer Therapy Targeting KIT Gene - Expands Global IP in Precision Oncology Platform

Clinical Trials Arena

5 months ago

Hoth Therapeutics reports interim data from Phase IIa trial of HT-001 for pruritus

Hoth Therapeutics Announces Positive Initial Data in Phase 2a Clinical Trial

PR Newswire

5 months ago

Hoth Therapeutics Announces Positive Initial Data in Phase 2a Clinical Trial

Hoth Therapeutics Collaborates with Washington University on NIH Grant Application Advancing Alzheimer's Program Using NK-1 Receptor Antagonist HT-ALZ

PR Newswire

5 months ago

Hoth Therapeutics Collaborates with Washington University on NIH Grant Application Advancing Alzheimer's Program Using NK-1 Receptor Antagonist HT-ALZ

Hoth Therapeutics Announces Positive Pre Clinical Data HT-ALZ Shows Promising Breakthrough in Alzheimer's Disease Research Acute treatment with HT-ALZ led to a rapid (~15%) reduction in brain interstitial fluid Aβ levels, within 20 hours

PR Newswire

5 months ago

Hoth Therapeutics Announces Positive Pre Clinical Data HT-ALZ Shows Promising Breakthrough in Alzheimer's Disease Research Acute treatment with HT-ALZ led to a rapid (~15%) reduction in brain interstitial fluid Aβ levels, within 20 hours

Hoth Therapeutics Receives USPTO Filing Receipt for HT-001 Formulation Patent Application, Expanding Existing Patent Coverage

PR Newswire

5 months ago

Hoth Therapeutics Receives USPTO Filing Receipt for HT-001 Formulation Patent Application, Expanding Existing Patent Coverage

Hoth Therapeutics Advances Cancer Fighting HT-KIT Program with New Patent Filing and Preclinical Study Initiation

PR Newswire

6 months ago

Hoth Therapeutics Advances Cancer Fighting HT-KIT Program with New Patent Filing and Preclinical Study Initiation

Hoth Therapeutics announces ‘positive’ results from study of HT-KIT

TipRanks

6 months ago

Hoth Therapeutics announces ‘positive’ results from study of HT-KIT

Hoth Therapeutics Announces Positive Preclinical Results for HT-KIT in Aggressive Cancer Gastrointestinal Stromal Tumors (GIST). HT-KIT Triggered Significant Tumor Cell Death as Early as 24 Hours Post-treatment

PR Newswire

6 months ago

Hoth Therapeutics Announces Positive Preclinical Results for HT-KIT in Aggressive Cancer Gastrointestinal Stromal Tumors (GIST). HT-KIT Triggered Significant Tumor Cell Death as Early as 24 Hours Post-treatment

Hoth Therapeutics Announces Plans to Submit Expanded Access Application for HT-001 to Support Cancer Patients in Need

PR Newswire

6 months ago

Hoth Therapeutics Announces Plans to Submit Expanded Access Application for HT-001 to Support Cancer Patients in Need

MT Newswires

6 months ago

Hoth Therapeutics Reports HT-001 Cream Efficacy in Case Study

Hoth Therapeutics Announces Positive Results for HT-001 in Treating EGFR Inhibitor-Associated Papulopustular Eruptions Findings to be Presented at the American Academy of Dermatology 2025 Annual Meeting

PR Newswire

6 months ago

Hoth Therapeutics Announces Positive Results for HT-001 in Treating EGFR Inhibitor-Associated Papulopustular Eruptions Findings to be Presented at the American Academy of Dermatology 2025 Annual Meeting

Hoth Therapeutics Announces Positive Findings on GDNF's Potential as a Game-Changer in Obesity Treatment and Reduced Fatty Liver Disease

PR Newswire

6 months ago

Hoth Therapeutics Announces Positive Findings on GDNF's Potential as a Game-Changer in Obesity Treatment and Reduced Fatty Liver Disease

Hoth Therapeutics Partners with OnTargetx R&D to Advance Research for Cancer fighting HT-KIT Cancer Therapeutic

PR Newswire

7 months ago

Hoth Therapeutics Partners with OnTargetx R&D to Advance Research for Cancer fighting HT-KIT Cancer Therapeutic

MT Newswires

8 months ago

Hoth Therapeutics Regains Compliance With Nasdaq Listing Rule

Hoth Therapeutics Regains Compliance with Nasdaq Listing Requirements

PR Newswire

8 months ago

Hoth Therapeutics Regains Compliance with Nasdaq Listing Requirements

Hoth Therapeutics Expands Intellectual Property Portfolio with Acquisition of New Patent Applications

PR Newswire

8 months ago

Hoth Therapeutics Expands Intellectual Property Portfolio with Acquisition of New Patent Applications

Hoth Therapeutics to Attend Sequire Investor Summit January 21-23, 2025

PR Newswire

8 months ago

Hoth Therapeutics to Attend Sequire Investor Summit January 21-23, 2025

Biotech Stock Roundup: NMRA Plunges on Study Failure, HOTH, VIR Soar on Study Data & More

Zacks

8 months ago

Biotech Stock Roundup: NMRA Plunges on Study Failure, HOTH, VIR Soar on Study Data & More

MT Newswires

8 months ago

Hoth Therapeutics Affirms No Plan to Raise Fresh Capital

Hoth Therapeutics Responds to Market Rumors and Shareholder Inquiries

PR Newswire

8 months ago

Hoth Therapeutics Responds to Market Rumors and Shareholder Inquiries

HOTH Stock Soars as Skin Toxicity Study in Cancer Patients Meets Goal

Zacks

8 months ago

HOTH Stock Soars as Skin Toxicity Study in Cancer Patients Meets Goal

Hoth Therapeutics Soars 215% on Breakthrough Cancer Treatment Success

GuruFocus.com

8 months ago

Hoth Therapeutics Soars 215% on Breakthrough Cancer Treatment Success

MT Newswires

8 months ago

Top Midday Gainers

MT Newswires

8 months ago

Hoth Therapeutics Says Interim Trial Results Show Drug to Mitigate Skin Cancer Treatment Toxicity Met Efficacy Endpoint

Hoth Therapeutics Achieves Breakthrough in Phase 2a Trial: HT-001 Delivers 100% Success in Combating Cancer Treatment Skin Toxicities

PR Newswire

8 months ago

Hoth Therapeutics Achieves Breakthrough in Phase 2a Trial: HT-001 Delivers 100% Success in Combating Cancer Treatment Skin Toxicities

MT Newswires

9 months ago

Sector Update: Health Care

MT Newswires

9 months ago

Top Midday Decliners

MT Newswires

9 months ago

Hoth Therapeutics Enters Patent Deal With Veterans Affairs Department to Develop Obesity Treatment

Hoth Therapeutics Enters Partnership with the Department of Veterans Affairs to Develop Obesity Treatment

PR Newswire

9 months ago

Hoth Therapeutics Enters Partnership with the Department of Veterans Affairs to Develop Obesity Treatment

MicroStrategy Copycats Are Buying Bitcoin as Price Nears $100,000

Barrons.com

10 months ago

MicroStrategy Copycats Are Buying Bitcoin as Price Nears $100,000

MT Newswires

10 months ago

Hoth Therapeutics Board Approves Purchase of up to $1 Million in Bitcoin; Shares Rise

MT Newswires

10 months ago

Hoth Therapeutics Shares Fall After Announcing $2.7 Million At-The-Market Equity Program

MT Newswires

10 months ago

Sector Update: Health Care Stocks Ease Late Afternoon

MT Newswires

10 months ago

Sector Update: Health Care

MT Newswires

10 months ago

Hoth Therapeutics Says Early Data Show HT-KIT Drug Stabilizes Tumor Growth; Shares Jump

Hoth Therapeutics Announces Update on Cancer Therapeutic HT-KIT Results Suggesting the Treatment Effectively Inhibited Tumor Growth in Preclinical Treatment Study

PR Newswire

10 months ago

Hoth Therapeutics Announces Update on Cancer Therapeutic HT-KIT Results Suggesting the Treatment Effectively Inhibited Tumor Growth in Preclinical Treatment Study

Hoth Therapeutics Awarded Key US Patent for Groundbreaking Alzheimer's Treatment and Prepares for Clinical Trials of HT-ALZ with Formulation Now Underway

PR Newswire

a year ago

Hoth Therapeutics Awarded Key US Patent for Groundbreaking Alzheimer's Treatment and Prepares for Clinical Trials of HT-ALZ with Formulation Now Underway

MT Newswires

a year ago

Hoth Therapeutics Says Alzheimer's Drug Shows Significant Preclinical Reductions in Astrocyte Activity

Hoth Therapeutics Announces Promising Preclinical Results for Alzheimer's Drug HT-ALZ

PR Newswire

a year ago

Hoth Therapeutics Announces Promising Preclinical Results for Alzheimer's Drug HT-ALZ

Hoth Stock Up as Lead Drug Heals Skin Toxicities in Cancer Patient

Zacks

a year ago

Hoth Stock Up as Lead Drug Heals Skin Toxicities in Cancer Patient

MT Newswires

a year ago

Hoth Therapeutics Shares Rise on Expanded Trial for Skin Toxicities Treatment

Hoth Therapeutics Announces Expansion of Clinical Sites for HT-001 Phase 2a Trial

PR Newswire

a year ago

Hoth Therapeutics Announces Expansion of Clinical Sites for HT-001 Phase 2a Trial

MT Newswires

a year ago

Hoth Therapeutics Reports Positive Resuts for Potential Cancer Treatment Side Effect Drug - Shares up Pre-Bell

Hoth Therapeutics Announces Positive Data from First-of-its-Kind Human Patient Treatment of EGFRI-Associated Skin Toxicities with HT-001

PR Newswire

a year ago

Hoth Therapeutics Announces Positive Data from First-of-its-Kind Human Patient Treatment of EGFRI-Associated Skin Toxicities with HT-001

Hoth and Aronnax partner for HT-KIT cancer therapy development

Pharmaceutical Technology

a year ago

Hoth and Aronnax partner for HT-KIT cancer therapy development

Hoth Therapeutics and Aronnax Inc. Enter Master Services Agreement For HT-KIT Cancer Therapeutic

PR Newswire

a year ago

Hoth Therapeutics and Aronnax Inc. Enter Master Services Agreement For HT-KIT Cancer Therapeutic

MT Newswires

a year ago

Top Midday Gainers

Hoth Therapeutics Partners with LTS Therapy Systems to Accelerate Novel Alzheimer's Treatment

PR Newswire

a year ago

Hoth Therapeutics Partners with LTS Therapy Systems to Accelerate Novel Alzheimer's Treatment

Hoth Therapeutics Expands Clinical Trial for Cancer Patients

PR Newswire

a year ago

Hoth Therapeutics Expands Clinical Trial for Cancer Patients

Hoth Therapeutics Announces Joint Development Agreement with Wise Systems International SRL to Utilize Artificial Intelligence for Drug Discovery

PR Newswire

a year ago

Hoth Therapeutics Announces Joint Development Agreement with Wise Systems International SRL to Utilize Artificial Intelligence for Drug Discovery

Hoth Therapeutics to Attend EF Hutton Annual Global Conference, May 15, 2024

PR Newswire

a year ago

Hoth Therapeutics to Attend EF Hutton Annual Global Conference, May 15, 2024

Hoth Therapeutics Announces Exercise of Warrants for $4.2 Million Gross Proceeds

PR Newswire

a year ago

Hoth Therapeutics Announces Exercise of Warrants for $4.2 Million Gross Proceeds

Hoth Therapeutics' Wholly Owned Subsidiary Merveille.ai, Advances AI-Driven Discovery for Obesity Treatment

PR Newswire

a year ago

Hoth Therapeutics' Wholly Owned Subsidiary Merveille.ai, Advances AI-Driven Discovery for Obesity Treatment

Hoth Therapeutics (HOTH) Up on Upbeat Alzheimer's Drug Data

Zacks

a year ago

Hoth Therapeutics (HOTH) Up on Upbeat Alzheimer's Drug Data

Hoth Therapeutics Announces Positive Data In Completed Study of Alzheimer's Disease Pre-Clinical Treatment with HT-ALZ

PR Newswire

a year ago

Hoth Therapeutics Announces Positive Data In Completed Study of Alzheimer's Disease Pre-Clinical Treatment with HT-ALZ

Hoth Therapeutics Retains Venable LLP to Expand Its Patent Portfolio

PR Newswire

2 years ago

Hoth Therapeutics Retains Venable LLP to Expand Its Patent Portfolio

Hoth Therapeutics Engages Altasciences to Perform Key Study for HT-KIT Cancer Fighting Therapeutic

PR Newswire

2 years ago

Hoth Therapeutics Engages Altasciences to Perform Key Study for HT-KIT Cancer Fighting Therapeutic

Hoth Therapeutics to Attend BIO CEO and Investor Conference, February 26-27, 2024

PR Newswire

2 years ago

Hoth Therapeutics to Attend BIO CEO and Investor Conference, February 26-27, 2024

PetVivo Holdings, Inc. Announces Release of Clinical Study Results Involving Canine Tolerance to Intra-articular Injections of Spryng™ with OsteoCushion™ Technology

GlobeNewswire

2 years ago

PetVivo Holdings, Inc. Announces Release of Clinical Study Results Involving Canine Tolerance to Intra-articular Injections of Spryng™ with OsteoCushion™ Technology

Impact Biomedical, Inc. Announces U.S. Patent Allowance of Laetose™ Technology Entitled "Low Glycemic Sugar Composition."

GlobeNewswire

2 years ago

Impact Biomedical, Inc. Announces U.S. Patent Allowance of Laetose™ Technology Entitled "Low Glycemic Sugar Composition."

Tortoise Announces 2023 Closed-End Fund Tax Characterization of Distributions and Release of Combined Annual Report

ACCESSWIRE

2 years ago

Tortoise Announces 2023 Closed-End Fund Tax Characterization of Distributions and Release of Combined Annual Report

Super League Aligns Team to Super Serve Rapidly Expanding Roster of Partners Committing Sizable Budgets to the 3D Web

GlobeNewswire

2 years ago

Super League Aligns Team to Super Serve Rapidly Expanding Roster of Partners Committing Sizable Budgets to the 3D Web

Golden Sun Education Group Limited Schedules Press Conference to Announce Strategic Transformation on January 26, 2024, in Wenzhou, Zhejiang Province

GlobeNewswire

2 years ago

Golden Sun Education Group Limited Schedules Press Conference to Announce Strategic Transformation on January 26, 2024, in Wenzhou, Zhejiang Province

Should You Invest in Duckhorn Portfolio (NAPA)?

Insider Monkey

2 years ago

Should You Invest in Duckhorn Portfolio (NAPA)?

Exela Technologies and XBP Europe Announce the Launch of Reaktr.ai to Provide Cybersecurity, Data Modernization and Multi-Cloud Management Enabled by AI

GlobeNewswire

2 years ago

Exela Technologies and XBP Europe Announce the Launch of Reaktr.ai to Provide Cybersecurity, Data Modernization and Multi-Cloud Management Enabled by AI

Institutions own 21% of Hawthorn Bancshares, Inc. (NASDAQ:HWBK) shares but retail investors control 56% of the company

Simply Wall St.

2 years ago

Institutions own 21% of Hawthorn Bancshares, Inc. (NASDAQ:HWBK) shares but retail investors control 56% of the company

After losing 41% in the past year, Neuronetics, Inc. (NASDAQ:STIM) institutional owners must be relieved by the recent gain

Simply Wall St.

2 years ago

After losing 41% in the past year, Neuronetics, Inc. (NASDAQ:STIM) institutional owners must be relieved by the recent gain

Wearable Devices: The Mudra Band Featured by Leading Tech Magazines, Mashable and VentureBeat

GlobeNewswire

2 years ago

Wearable Devices: The Mudra Band Featured by Leading Tech Magazines, Mashable and VentureBeat

IZEA Worldwide (IZEA) Boosts Portfolio in Influencer Marketing

Zacks

2 years ago

IZEA Worldwide (IZEA) Boosts Portfolio in Influencer Marketing

Newsfile

2 years ago

Advanced Health Intelligence CEO to Deliver Investor Presentation in Atlantic City

Hoth Therapeutics Announces it Received FDA Approval to Expand HT-001 Clinical Trial to Treat Severely Ill Patients

PR Newswire

2 years ago

Hoth Therapeutics Announces it Received FDA Approval to Expand HT-001 Clinical Trial to Treat Severely Ill Patients

SEALSQ Announces Closing of the Second $10.0 Million Tranche of Convertible Notes and Warrants Private Placement

GlobeNewswire

2 years ago

SEALSQ Announces Closing of the Second $10.0 Million Tranche of Convertible Notes and Warrants Private Placement

Spectral AI Begins Enrollment in Pivotal Study to Validate DeepView AI® for Burn Injuries

GlobeNewswire

2 years ago

Spectral AI Begins Enrollment in Pivotal Study to Validate DeepView AI® for Burn Injuries

Trinity Place Holdings Inc. Enters Into Recapitalization Transactions

Business Wire

2 years ago

Trinity Place Holdings Inc. Enters Into Recapitalization Transactions

YS Biopharma Announces Changes to its Board Committees

PR Newswire

2 years ago

YS Biopharma Announces Changes to its Board Committees

IHT DECLARES 54TH CONSECUTIVE ANNUAL DIVIDEND AS REVENUES CONTINUE TO CLIMB WITH RECORD DECEMBER

GlobeNewswire

2 years ago

IHT DECLARES 54TH CONSECUTIVE ANNUAL DIVIDEND AS REVENUES CONTINUE TO CLIMB WITH RECORD DECEMBER

Could The Market Be Wrong About GEN Restaurant Group, Inc. (NASDAQ:GENK) Given Its Attractive Financial Prospects?

Simply Wall St.

2 years ago

Could The Market Be Wrong About GEN Restaurant Group, Inc. (NASDAQ:GENK) Given Its Attractive Financial Prospects?

Hoth Therapeutics Announces Expansion of FDA Cleared First-In-Human Clinical Trial For Cancer Patients of HT-001 at University of Miami

PR Newswire

2 years ago

Hoth Therapeutics Announces Expansion of FDA Cleared First-In-Human Clinical Trial For Cancer Patients of HT-001 at University of Miami

KWESST Announces Delay in Filing Year-End Reporting Documents

Newsfile

2 years ago

KWESST Announces Delay in Filing Year-End Reporting Documents

Secure Medical Chooses Edgio for Fast, Secure Delivery of Telehealth Services

Business Wire

2 years ago

Secure Medical Chooses Edgio for Fast, Secure Delivery of Telehealth Services

Lightbridge and Centrus Energy Enter into a Contract to Conduct a FEED Study for a Lightbridge Pilot Fuel Fabrication Facility in Piketon, Ohio

PR Newswire

2 years ago

Lightbridge and Centrus Energy Enter into a Contract to Conduct a FEED Study for a Lightbridge Pilot Fuel Fabrication Facility in Piketon, Ohio

Share on Social Networks: